StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research note issued to investors on Saturday morning. The brokerage issued a sell rating on the stock.
Oragenics Stock Performance
Shares of Oragenics stock opened at $0.52 on Friday. The company has a market capitalization of $2.33 million, a P/E ratio of -0.06 and a beta of 0.50. Oragenics has a 1 year low of $0.47 and a 1 year high of $7.74. The company’s fifty day moving average is $1.09 and its two-hundred day moving average is $1.41.
Oragenics (NYSE:OGEN – Get Free Report) last announced its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.
Hedge Funds Weigh In On Oragenics
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Stories
- Five stocks we like better than Oragenics
- What is the Shanghai Stock Exchange Composite Index?
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- Industrial Products Stocks Investing
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.